enlicitide

Ask MedXY AI

Latest news

Tag

CardiologyenlicitideNonstatin lipid-lowering therapy

Enlicitide: A Breakthrough Oral PCSK9 Inhibitor Offering Superior LDL-C Reduction Compared to Established Oral Nonstatin Therapies

By MedXY|Aug 18, 2026

This phase 3 trial demonstrates that the oral PCSK9 inhibitor enlicitide achieves significantly greater LDL-C reduction than bempedoic acid, ezetimibe, or their combination in statin-treated adults at elevated cardiovascular risk, with comp

CardiologyenlicitideLDL-C

Oral PCSK9 Inhibitor Enlicitide Produces ~58% LDL‑C Reduction in Heterozygous Familial Hypercholesterolemia: A Phase 3 Randomized Trial

By MedXY|Nov 10, 2025

In adults with heterozygous familial hypercholesterolemia on statin therapy, oral enlicitide decanoate reduced LDL‑C by ~58% at 24 weeks versus placebo and was well tolerated through 52 weeks.